Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Debt to Equity (2016 - 2025)

ImmunityBio (IBRX) has disclosed Debt to Equity for 12 consecutive years, with -$0.65 as the latest value for Q4 2025.

  • Quarterly Debt to Equity fell 11.32% to -$0.65 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.65 through Dec 2025, down 11.32% year-over-year, with the annual reading at -$0.65 for FY2025, 11.32% down from the prior year.
  • Debt to Equity for Q4 2025 was -$0.65 at ImmunityBio, down from -$0.6 in the prior quarter.
  • The five-year high for Debt to Equity was -$0.16 in Q2 2024, with the low at -$2.0 in Q2 2021.
  • Average Debt to Equity over 5 years is -$0.78, with a median of -$0.6 recorded in 2025.
  • The sharpest move saw Debt to Equity tumbled 4025.26% in 2021, then skyrocketed 68.54% in 2024.
  • Over 5 years, Debt to Equity stood at -$1.64 in 2021, then soared by 59.16% to -$0.67 in 2022, then surged by 60.45% to -$0.27 in 2023, then plummeted by 119.66% to -$0.58 in 2024, then dropped by 11.32% to -$0.65 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at -$0.65, -$0.6, and -$0.54 for Q4 2025, Q3 2025, and Q2 2025 respectively.